Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
News Editor's pick

Waters CFO sets out 2027 growth starting point nine months into BD combination, at Jefferies London

Waters chief financial officer Amol Chaubal told the Jefferies Global Healthcare Conference in London that the BD integration is on track, putting 2027 starting assumptions at about 7.25% growth for legacy Waters and 4.75% for the BD businesses.

A Waters ACQUITY UPLC liquid chromatography system on a laboratory bench, with the Waters logo on a white card
A Waters ACQUITY UPLC system (file photo). Waters' Amol Chaubal spoke at the Jefferies Global Healthcare Conference in London on November 17, 2026. Photo: “Picture of a UPLC device” by Groep29 BFW, via Wikimedia Commons, public domain; cropped, Waters logo added by Onyx.
Table of Contents

Waters Corporation used a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 to set out how it expects growth to build in 2027, nine months after combining with BD’s Biosciences and Diagnostic Solutions businesses. Senior vice president and chief financial officer Amol Chaubal said the integration is on track and that the company now faces a different problem: “the expectations are running ahead of us”.

Waters: the BD deal, nine months in

Chaubal said investors a year ago doubted the BD businesses could grow. Excluding China, those businesses are now growing at about 6%, Chaubal said, while legacy Waters is growing at roughly 9% to 9.5%.

Chaubal said Waters has reached its $200 million run rate of cost synergies. The company expects $50 million of revenue synergies in 2026 and a further $60 million in 2027. The deal closed on February 9, 2026.

Chaubal said “market conditions are as good as they have been for quite some time”.

A starting point for 2027

Waters has guided to mid-single-digit plus organic growth in 2027 as a starting assumption. Chaubal put that at about 7.25% for legacy Waters and 4.75% for the BD businesses, adding that the BD figure does not yet reflect new launches. Waters said that adds up to about 6% for the whole company.

On margin, Waters expects 100 basis points of expansion in 2027, from an expected adjusted operating margin of 28.2% in 2026 to 29.2%. Chaubal said $75 million of the $200 million cost synergies are in this year’s results, leaving about $125 million for next year, a margin gain partly offset by six weeks of BD not consolidated in 2026.

China and the replacement cycle

Waters said at the event that its 2027 assumption has China growing at about 6%, in line with the company. Waters has reported that its Biosciences business in China returned to growth in the third quarter for the first time in 10 quarters.

Chaubal said the instrument replacement cycle in legacy Waters has runway into 2028, with China’s branded generics makers yet to start. Without the replacement cycle, Chaubal said, “when you strip that out, we’re still growing 8%”.

For the BD businesses, Chaubal pointed to the FACSDiscover A7 spectral cell analyzer and the BACTEC FXI blood culture system. Chaubal said A7 is largely sold for cash, so catch-up replacements should show in instrument growth next year, while about half of the BACTEC business runs on a reagent rental model that spreads revenue over about five years.

AI and Empower

Waters said Empower, its chromatography software, is moving customers from perpetual licenses to subscriptions, and that its new AI features are only available on subscription. Waters says Empower has more than 500,000 users. Waters said the switch diluted instrument growth by about 50 basis points this year and should be neutral in 2027.

Waters said AI in quality control labs must be built natively within Empower so that workflows remain compliant.

Chaubal put AI-related revenue this year in the high single-digit millions of dollars in each of materials science sales to semiconductor and data center customers, flow reagents and chemistry, and tech-bio labs. “There has never been a deep need for high throughput, high reliable instruments in drug discovery,” Chaubal said, adding that automation is changing that, but that it is too early to “call it a trend”.

Flow reagents and proteomics

Waters has reported that its research flow reagents grew at high single digits in the third quarter, up from low single digits. Waters credited better market conditions, faster fulfillment, pricing and the company’s Real Dyes for spectral flow cytometers.

In proteomics, Chaubal said the Xevo MRT mass spectrometer has grown in lipidomics and metabolomics, and that Waters’ acquisition of MOBILion, announced on November 3, is meant to take it into plasma proteomics. Chaubal said Waters should be able to gain about 10% of what Waters sizes as a $2 billion LC-MS proteomics market.

About Waters

Waters Corporation (NYSE: WAT) is a life sciences and diagnostics company, with analytical technologies, informatics and service focused on regulated, high-volume testing. It has about 15,000 employees.


Sources: Waters Corporation fireside chat, Jefferies Global Healthcare Conference, London, November 17, 2026; Waters third quarter 2026 results and earnings call (November 3, 2026); Waters MOBILion acquisition (November 3, 2026); Waters Empower peak integration announcement; Waters FACSDiscover A7 launch

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments

More News ↗